Obesity: Why be concerned?

American Journal of Medicine

Volumn 122, Issue 4 SUPPL. 1, 2009, Pages

  Brown, W Virgil ^a   Fujioka, Ken ^b   Wilson, Peter W F ^a   Woodworth, Kristina A ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS CLINIC   (United States)

^c SciMantis Communications Inc   (United States)

Author keywords

Cardiovascular disease; Health care costs; Lipoproteins; Metabolic syndrome; Obesity; Risk factor

Indexed keywords

ECONOMICS; HEALTH CARE COST; HUMAN; OBESITY; PUBLIC HEALTH; REVIEW; RISK FACTOR; UNITED STATES;

HEALTH CARE COSTS; HUMANS; OBESITY; PUBLIC HEALTH; RISK FACTORS; UNITED STATES;

EID: 66149141806     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.002     Document Type: Article

References (54)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999- 2004. JAMA. 2006;295:1549-1555.
2. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-1145. (Pubitemid 40365358)
3. National Heart, Lung, and Blood Institute (NHLBI). The Evidence Report: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, Dept of Health and Human Services, September 1998. NIH Publication No. 98-4083.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
6. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214. (Pubitemid 36523358)
7. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257. (Pubitemid 39202341)
8. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689. (Pubitemid 32893993)
9. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872.
10. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 2002;5:377-383. (Pubitemid 40684658)
11. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200. (Pubitemid 36629866)
12. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-355. (Pubitemid 40277057)
13. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-1289. (Pubitemid 41127348)
14. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45:623-634.
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428. (Pubitemid 40523737)
16. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462. (Pubitemid 36173203)
17. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small lowdensity lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006; 113:20-29. (Pubitemid 43958484)
18. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928. (Pubitemid 44331360)
19. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91:3A-6A. (Pubitemid 36351456)
20. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S83-S86. (Pubitemid 36928964)
21. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381-387. (Pubitemid 39359480)
22. Brown WV. High-density lipoprotein and transport of cholesterol and triglyceride in blood. J Clin Lipidol. 2007;1:7-19. (Pubitemid 46696621)
23. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225-1228. (Pubitemid 41615541)
24. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716. (Pubitemid 35403784)
25. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111:1883-1890. (Pubitemid 40570207)
26. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165:2644-2650. (Pubitemid 41785063)
27. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
28. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med. 1999;341:427-434. (Pubitemid 29362517)
29. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol. 1997;145:614-619. (Pubitemid 27154864)
30. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
31. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res. 1999;7:523-531. (Pubitemid 129710616)
32. Bhattacharya J, Bundorf MK. The incidence of the healthcare costs of obesity. National Bureau of Economic Research Working Paper Series. Cambridge, MA: National Bureau of Economic Research, May 2005. Available at: http://www.nber.org/papers/w11303. Accessed June 5, 2007.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
34. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. (Pubitemid 32378388)
35. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24-32. (Pubitemid 36232091)
36. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-1638. (Pubitemid 36459468)
37. Lukanova A, Bjor O, Kaaks R, et al. Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. Int J Cancer. 2006;118:458-466. (Pubitemid 41779087)
38. Calle EE, Thun MJ. Obesity and cancer. Oncogene. 2004;23:6365-6378. (Pubitemid 39265505)
39. Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J. 2006;13:203-210. (Pubitemid 44083437)
40. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004;25:735-741. (Pubitemid 38647933)
41. Lavie P, Herer P, Lavie L. Mortality risk factors in sleep apnoea: a matched case-control study. J Sleep Res. 2007;16:128-134.
42. Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev. 2006;7:239-250. (Pubitemid 44086901)
43. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007;66: 433-439. (Pubitemid 46580460)
44. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533. (Pubitemid 39141140)
45. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
46. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79. (Pubitemid 36055340)
47. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44. (Pubitemid 41115552)
48. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166: 2081-2086. (Pubitemid 44631395)
49. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome: what are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol. 2006;176(pt 1):1524-1527; discussion 1527-1528.
50. Riedner CE, Rhoden EL, Ribeiro EP, Fuchs SC. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol. 2006;176(pt 1):1519-1523. (Pubitemid 44307230)
51. Alagna S, Cossu ML, Gallo P, et al. Biliopancreatic diversion: longterm effects on gonadal function in severely obese men. Surg Obes Relat Dis. 2006;2:82-86.
52. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. 1992;128:941-944.
53. Garcia Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol. 2002;3:497-506. (Pubitemid 35007067)
54. Garcia-Hidalgo L, Orozco-Topete R, Gonzalez-Barranco J, Villa AR, Dalman JJ, Ortiz-Pedroza G. Dermatoses in 156 obese adults. Obes Res. 1999;7:299-302. (Pubitemid 129710590)